スタッフの主な業績

Breast. 2018 Apr 23;40:67-75

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.

Asia Pac J Clin Oncol. 2018 Mar 1. doi: 10.1111/ajco.12863

A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y, Uchida Y, Shirakawa K, Kanauchi H, Niwa T, Nishioka K, Tada K, Hashimoto M, Yasuda H, Sugiura R, Kawabata H, Seto Y, Ogawa T.

Breast Cancer. 2018 May;25(3):343-349

Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T.

Int J Mol Sci. 2017 Sep 8;18(9). pii: E1931.

Hidetaka Kawabata, Kotaro Azuma, Kazuhiro Ikeda, Ikuko Sugitani, Keiichi Kinowaki, Takeshi Fujii, Akihiko Osaki, Toshiaki Saeki, Kuniko Horie-Inoue, Satoshi Inoue
TRIM44 is a poor prognostic factor for breast cancer patients as a modulator of NF-κB signaling

Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186

Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y.
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.

Breast Cancer Res Treat. 2014 May;145(1):143-53

Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).

The Breast 2014 August 23(4) 466-72

Maki Tanioka, Masaoki Sasaki, Akihiko Shimomura, Makoto Fujishima, Mihoko Doi, Kazuo Matsuura, Toshiko Sakuma, Kenichi Yoshimura, Toshiaki Saeki, Masahiro Ohara, Junji Tsurutani,Masahiro Watatani, Toshimi Takano, Hidetaka Kawabata, Hirofumi Mukai, Yoichi Naito, Koichi Hirokaga, Shintaro Takao and Hironobu Minami
Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status

Chemotherapy 2013; 59(2):93-98

Marie Hanaoka, Hidetaka Kawabata, Tsuguo Iwatani, Toshimi Takano, Daishu Miura Reduction of Toxicity by Reversing the Order of Infusion of Docetaxel and Cyclophosphamide.

J Cancer 2013 4:519-523

Miura Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, and Takano T:
The safety of chemotherapy for breast cancer patients with hepatitis C virus infection.

Psycho-Oncology 2012 (Article first published online:DOI: 10.1002/pon.3023)

Tsuguo Iwatani, Ayako Matsuda, Hidetaka Kawabata, Daishu Miura, Eisuke Matsushima
Predictive factors for psychological distress related to diagnosis of breast cancer.

J.Clin.Oncol 2011,29, e113-115

Tsuguo Iwatani, Hidetaka Kawabata, Daishu Miura, Yasunori Ota, Kenichi Ohashi
Complete Spontaneous Regression of Primary Diffuse Large B-cell Lymphoma of the Breast

N Engl J Med 2011;365:1056-7

Marie Hanaoka, Toshimi Takano, Hidetaka Kawabata (Comment on: N Engl J Med 2011; 364: 2381-2391)
Exemestane for Breast-Cancer Prevention.

Lancet 2011,377,121

Keisuke Shigeta, Yuji Miura,Yoichi Naito, Toshimi Takano
Cabazitaxel for castration-resistant prostate cancer

N Engl J Med 363:2371, 2010

Naito Y Miura Y Takano T (Comment on: N Engl J Med 363:943-53, 2010)
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

N Engl J Med 361:2485-6, 2009

Takano T (Comment on: N Engl J Med 361:947-57, 2009)
Treatment of lung cancer.

Breast Cancer, 2009, DOI 10.1007/s12282-009-0149-1

Tsuguo Iwatani, Hidetaka Kawabata, Daishu Miura, Naoko Inoshita, Yasunori Ohta
Nodular fasciitis of the breast.

J Clin Oncol 27:464-465, 2009

Takano T, Ota S, Hori A, Seki N, and Eguchi K:
Can Epidermal Growth Factor Receptor?Fluorescent in Situ Hybridization Predict Clinical Benefit From Cetuximab Treatment in Patients With Non?Small-Cell Lung Cancer?

J Clin Oncol 26: 5589-5595, 2008

Takano T, Fukui T, Ohe Y, et al:
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.

Clin Cancer Res 13:5385-5390, 2007

Takano T, Ohe Y, Tsuta K, et al:
Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Gefitinib.

J Clin Oncol 24:1221, 2006

Takano T, Ohe Y, Sekine I, Kunitoh H, Yoshida T, and Tamura T:
In Reply. (Reply to: J Clin Oncol 24:1219-1220, 2006)

N Engl J Med 353:1739-41, 2005

Takano T and Ohe Y:
Erlotinib in lung cancer. (Comment on: N Engl J Med 353:123-32 and 133-44, 2005)

J Clin Oncol 23:6829-37, 2005

Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

Lancet,2001,358,1018

Hidetaka Kawabata, Takafumi Ueno
Screening recommendation for women taking tamoxifen

Lancet 2000,355,238

Takafumi Ueno、Hidetaka Kawabata
Tobacco and health care professionals in Japan

Lancet 1999,354,1207

Hidetaka Kawabata,Takafumi Ueno
Early Lung Cancer Action Project.

Lancet 1999,353,2077

Hidetaka Kawabata,Takafumi Ueno
Controversy over cancer chemotherapy in Japan